Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 11/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30187192 | 1.00 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2CNR2KDM4ETDP1 | |
| SCHEMBL24003154 | 0.92 | CNR2 (0.53) | ALDH1A1SMN1; SMN2CNR2KDM4ELMNA | |
| SCHEMBL30187103 | 0.92 | CNR2 (0.53) | ALDH1A1SMN1; SMN2CNR2KDM4ELMNA | |
| SCHEMBL30187154 | 0.91 | CNR2 (0.61) | ALDH1A1SMN1; SMN2CNR2CNR1 | |
| SCHEMBL24003102 | 0.91 | CNR2 (0.61) | ALDH1A1SMN1; SMN2CNR2CNR1 | |
| SCHEMBL24002697 | 0.91 | CNR2 (0.49) | ALDH1A1SMN1; SMN2CNR2KDM4ELMNA | |
| SCHEMBL30187163 | 0.90 | CNR2 (0.53) | ALDH1A1SMN1; SMN2CNR2CNR1 | |
| SCHEMBL24003080 | 0.90 | CNR2 (0.53) | ALDH1A1SMN1; SMN2CNR2CNR1 | |
| SCHEMBL24003104 | 0.85 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2CNR2KDM4ELMNA | |
| SCHEMBL24937592 | 0.84 | CNR2 (0.68) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | ALDH1A1 3600/4885SMN1; SMN2 3507/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.